Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

When Will Kids Get COVID Vaccines?

By Keith Speights - Dec 27, 2020 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some teens are already receiving vaccines. But it could be a while longer for younger kids.

Adults across the U.S. have already begun to receive COVID-19 vaccines developed by Pfizer ( PFE -1.98% ) and Moderna ( MRNA -4.54% ). But what about kids? In this Motley Fool Live video recorded on Dec. 18, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and writer Keith Speights discuss when COVID vaccines will be evaluated for use in children.

Corinne Cardina: Another question. Sanjay asked, "At what point will the vaccine be evaluated for safety to administer to kids?" I feel like a lot of parents out there in the world want to know this. It impacts schools opening.

I actually have an interesting article I read about this that I will drop in the chat from the conversation. But Moderna is actually starting to look at testing their vaccine in people age 12 to 18 last week. Keith, are there any other companies that are looking at the question of children and adolescents?

Keith Speights: Pfizer has already begun testing kids ages 12 and up. Like I said earlier, Pfizer's Emergency Use Authorization is for individuals ages 16 and up. So teenagers 16 to 17 years old can take the Pfizer vaccine, whereas assuming Moderna wins EUA, theirs will be 18 and up.

So Pfizer has already started studying children ages just 12 and up; AstraZeneca ( AZN -0.15% ) has announced some plans to do so as well. I would anticipate that others like Johnson & Johnson ( JNJ -0.14% ) will probably expand their studies to include children down to 12.

The real question is, "What happens after that, and do they go down to much younger children?" I don't think any of the companies have talked a lot about that so far, so I don't think that's as pressing of a priority just now, but I would anticipate that once they get some good data on kids 12 and up, then that would be a logical next step to start taking a look at younger children. But that remains to be seen for now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$53.60 (-1.98%) $-1.08
Johnson & Johnson Stock Quote
Johnson & Johnson
$157.86 (-0.14%) $0.22
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.80 (-0.15%) $0.09
Moderna, Inc. Stock Quote
Moderna, Inc.
$296.51 (-4.54%) $-14.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.